Clinical significance of sarcopenia in cancer chemotherapy

• Project/Area Number: 26460626
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Applied pharmacology
• Research Institution: Nagoya University
• Principal Investigator: Ando Yuichi 名古屋大学, 医学部附属病院, 教授 (10360083)
• Co-Investigator(Kenkyū-buntansha): 満間 綾子 名古屋大学, 医学部附属病院, 病院講師 (10467326) ; 浦川 浩 名古屋大学, 医学部附属病院, 病院講師 (60584753) ; 下方 智也 名古屋大学, 医学部附属病院, 病院助教 (70612745)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000); Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
• Keywords: サルコペニア / 分子標的治療薬 / がん薬物療法

Outline of Final Research Achievements

The aim of this study is investigated sarcopenia in cancer patients who underwent cancer chemotherapy in order to test the hypothesis that those patients with sarcopenia are more likely to experience severe toxicity and then poorly tolerate the treatment. First, we retrospectively analyzed the change of skeletal muscle mass in patients treated with an mTOR inhibitor and reported that the muscle mass was significantly reduced by treatment. Subsequently, an observational study was conducted to prospectively evaluate sarcopenia up to for 6 months in cancer patients who received a kinase inhibitor containing mTOR inhibitor. Of the 28 patients enrolled, 17 and 7 patients completed the 6-month and 3-month follow-ups, respectively. Final analysis of the results is in progress.

Research Products

• [Journal Article] Muscle wasting associated with the long-term use of mTOR inhibitors. (2016)
  • Author(s): Bishal Gyawali, Tomoya Shimokata, Kazunori Honda, Chihiro Kondoh, Naomi Hayashi, Yasushi Yoshino, Naoto Sassa, Yasuyuki Nakano, Momokazu Gotoh, Yuichi Ando.
  • Journal Title: Mol Clin Oncol. Volume: 5 Issue: 5 Pages: 641-646
  • DOI: 10.3892/mco.2016.1015
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Low skeletal muscle density is associated with poor survival in patients with metastatic gastric cancer receiving chemotherapy. (2016)
  • Author(s): Nomi Hayashi, Yuichi Ando, Bishal Gyawali, Tomoya Shimokata, Osamu Maeda, Masahide Fukaya, Hidemi Goto, Masato Nagino and Yasuhiro Kodera.
  • Journal Title: Oncol Rep Volume: 35 Issue: 3 Pages: 1727-1231
  • DOI: 10.3892/or.2015.4475
  • Peer Reviewed / Acknowledgement Compliant
• [Presentation] Temsirolimus induced muscle loss. (2016)
  • Author(s): Bishal Gyawali, Tomoya Shimokata, Takefumi Mizutani, Osamu Maeda, Naoto Sassa, Yasushi Yoshino, Momokazu Gotoh, Yuichi Ando.
  • Organizer: The 2nd Asian Conference for Frailty and Sarcopenia
  • Place of Presentation: 今池ガスビルホール（愛知県名古屋市）
  • Year and Date: 2016-11-04
  • Int'l Joint Research
• [Presentation] Loss of muscle mass associated with the long term use of mTOR inhibitors. (2016)
  • Author(s): Bishal Gyawali, Tomoya Shimokata, Kazunori Honda, Chihiro Kondoh, Naomi Hayashi, Yasushi Yoshino, Naoto Sassa, Yasuyuki Nakano, Momokazu Gotoh, Yuichi Ando
  • Organizer: 第14回日本臨床腫瘍学会学術集会
  • Place of Presentation: 神戸国際展示場・神戸国際会議場（兵庫県神戸市）
  • Year and Date: 2016-07-28
• [Presentation] 進行再発胃がん患者における筋肉量評価について (2015)
  • Author(s): 林直美、ビシャール・ギャワリ、下方智也、前田修、後藤秀実、梛野正人、小寺泰弘、安藤雄一．
  • Organizer: 第48回制癌剤適応研究会
  • Place of Presentation: オークラアクトシティホテル浜松（浜松市）
  • Year and Date: 2015-03-20